JP2023546970A - 高血圧のためのｃｙｐ１１ｂ２ベータヒドロキシラーゼ阻害剤 - Google Patents

高血圧のためのｃｙｐ１１ｂ２ベータヒドロキシラーゼ阻害剤 Download PDF

Info

Publication number
JP2023546970A
JP2023546970A JP2023525457A JP2023525457A JP2023546970A JP 2023546970 A JP2023546970 A JP 2023546970A JP 2023525457 A JP2023525457 A JP 2023525457A JP 2023525457 A JP2023525457 A JP 2023525457A JP 2023546970 A JP2023546970 A JP 2023546970A
Authority
JP
Japan
Prior art keywords
subject
cyp
plasma
hydroxylase inhibitor
renin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546970A5 (https=
Inventor
テイラー スリングズビー，ブライアン
コノリー ワット，ウィリアム
ロッドマン，デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mineralys Therapeutics Inc
Original Assignee
Mineralys Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mineralys Therapeutics Inc filed Critical Mineralys Therapeutics Inc
Publication of JP2023546970A publication Critical patent/JP2023546970A/ja
Publication of JP2023546970A5 publication Critical patent/JP2023546970A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023525457A 2020-10-26 2021-10-25 高血圧のためのｃｙｐ１１ｂ２ベータヒドロキシラーゼ阻害剤 Pending JP2023546970A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105745P 2020-10-26 2020-10-26
US63/105,745 2020-10-26
US202163223719P 2021-07-20 2021-07-20
US63/223,719 2021-07-20
PCT/US2021/056499 WO2022093714A1 (en) 2020-10-26 2021-10-25 Cyp11b2 beta hydroxylase inhibitors for hypertension

Publications (2)

Publication Number Publication Date
JP2023546970A true JP2023546970A (ja) 2023-11-08
JP2023546970A5 JP2023546970A5 (https=) 2024-10-30

Family

ID=81384356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525457A Pending JP2023546970A (ja) 2020-10-26 2021-10-25 高血圧のためのｃｙｐ１１ｂ２ベータヒドロキシラーゼ阻害剤

Country Status (4)

Country Link
US (1) US20240009201A1 (https=)
EP (1) EP4232011A4 (https=)
JP (1) JP2023546970A (https=)
WO (1) WO2022093714A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230069126A (ko) * 2020-09-15 2023-05-18 미쓰비시 타나베 파마 코퍼레이션 트리아진 화합물의 염, 그 결정형 및 제조 방법
CN117957213A (zh) * 2021-07-20 2024-04-30 矿物疗法公司 包括经二取代的1,2,4-三嗪化合物的盐的可溶性药物组合物
TW202339758A (zh) * 2022-01-19 2023-10-16 美商礦物質醫療股份有限公司 藉由週期性遏制醛固酮合酶治療高血壓之方法
JP2025527706A (ja) * 2022-08-23 2025-08-22 ミネラリス・セラピューティクス・インコーポレイテッド 肥満対象における高血圧を治療する方法
CA3265668A1 (en) * 2022-08-23 2024-02-29 Mineralys Therapeutics, Inc. METHODS OF TREATING HYPERTENSION WITH A COMBINATION OF AN ALDOSTERONE SYNTHASE INHIBITOR AND A DIURETIC
KR20250057804A (ko) 2022-09-02 2025-04-29 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물
WO2025059569A1 (en) * 2023-09-15 2025-03-20 Mineralys Therapeutics, Inc. Process for producing triazine compound
CN120904169A (zh) * 2024-05-30 2025-11-07 浙江扬厉医药技术有限公司 一种n-烷氧基乙酰胺类化合物、其药物组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015163427A1 (ja) * 2014-04-24 2015-10-29 田辺三菱製薬株式会社 新規二置換１，２，４－トリアジン化合物
JP2017081911A (ja) * 2015-10-22 2017-05-18 田辺三菱製薬株式会社 医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596302A (en) * 2009-05-15 2014-01-31 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
DE102012200360A1 (de) * 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
JP6067181B2 (ja) * 2013-04-30 2017-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロンシンターゼ阻害薬

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015163427A1 (ja) * 2014-04-24 2015-10-29 田辺三菱製薬株式会社 新規二置換１，２，４－トリアジン化合物
JP2017081911A (ja) * 2015-10-22 2017-05-18 田辺三菱製薬株式会社 医薬組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HYPERTENSION, vol. 56, JPN6025053591, 2010, pages 831 - 838, ISSN: 0005765633 *
PHARMACOLOGICAL RESEARCH, vol. Vol.154,104311, JPN6025053593, 15 June 2019 (2019-06-15), pages 1 - 12, ISSN: 0005765634 *

Also Published As

Publication number Publication date
EP4232011A4 (en) 2024-11-27
EP4232011A1 (en) 2023-08-30
WO2022093714A1 (en) 2022-05-05
US20240009201A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
JP2023546970A (ja) 高血圧のためのｃｙｐ１１ｂ２ベータヒドロキシラーゼ阻害剤
ME00479B (me) Lijek za profilaksu i tretman arterioskleroze i hipertenzije
US20100204252A1 (en) Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
CN111417388A (zh) 治疗肌营养不良症的方法
AU2018380155B2 (en) Compositions for the treatment of breast and prostate cancer
WO2021229979A1 (ja) 脳小血管病の予防又は治療用医薬組成物
US20250099475A1 (en) Methods of treating hypertension by periodic suppression of aldosterone synthase
AU2018295387A1 (en) Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
CN101316626A (zh) 用于降低血压的方法
WO2011111066A2 (en) Composition and uses thereof
US20260053812A1 (en) Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic
US20260053811A1 (en) Methods of treating hypertension in obese subjects
EP4183393A1 (en) Compounds for treating hepatocellular carcinoma
UA82216C2 (uk) Лікарський засіб на основі антагоніста рецептора ангіотензину іі та блокатора кальцієвих каналів для профілактики і лікування кардіоваскулярних захворювань
WO2025128614A1 (en) Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
AU2007304216B2 (en) Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CN107405348A (zh) Raf抑制剂与紫杉烷的组合
RU2024129466A (ru) Белумосудил для лечения хронической дисфункции аллотрансплантата легкого
WO2021142237A1 (en) Methods for administering lucitanib and combinations thereof
EP4010019A1 (en) Use of the anti-p-selectin antibody crizanlizumab for treating sickle cell nephropathy and chronic kidney disease associated with sickle cell disease
WO2021049612A1 (ja) 急性心不全における体液貯留改善薬
WO2005073218A1 (ja) バイパス術に伴う血管攣縮治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260403